Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
+44 1478 350008
ISSN: 2329-8790
+44 1478 350008
Shigeki Takemoto
Clinical Laboratory, National Hospital Organization Kumamoto Medical Center,
Address: 1-5 Ninomaru, Chuoku, Kumamoto 860-0008
Japan
Research Article
Clinical Value of Serum Soluble CD30 Levels in Adult T-Cell Leukemia/ Lymphoma
Author(s): Ratiorn Pornkuna, Shigeki Takemoto, Michihiro Hidaka, Fumio Kawano and Yoshio HagaRatiorn Pornkuna, Shigeki Takemoto, Michihiro Hidaka, Fumio Kawano and Yoshio Haga
Adult T-cell leukemia/lymphoma (ATLL) is an incurable neoplasm of mature T-cells with a median survival time of approximately one year. The aim of this study was to compare the clinical value of soluble CD30 (sCD30) levels with soluble IL-2 receptor α chain (sIL-2R) levels in two different clinical settings of ATLL patients; before an initial therapy of chemotherapy or gastric resection (n=32), and before allogeneic hematopoietic stem cell transplantation (HSCT; n=24). All patients completed the 2-year follow-up. Both sIL-2R (p=0.016) and sCD30 (p=0.030) levels were significant predictors of overall survival before the initial therapy. The number of ATLL cells in peripheral blood (PB) was correlated with sCD30 levels (Spearman’s correlation coefficient, ρ=0.46; p=0.009) but not with sIL-2R levels (ρ=0.16; P=0.38). Patients who survived for longer than two years, an.. View More»
DOI:
10.4172/2329-8790.1000167